AI English summary of an SEC filing — figures as filed
Cencora CORCencora said it will acquire Retina Consultants of America (RCA) for cash based on an enterprise value of approximately $4.6 billion, subject to a working capital and net-debt adjustment. It said it expects to hold approximately 85% ownership in RCA at closing.
Key points
AI summaryCencora said it will acquire Retina Consultants of America (RCA) for cash based on an enterprise value of approximately $4.6 billion, subject to a working capital and net-debt adjustment. It said it expects to hold approximately 85% ownership in RCA at closing.
The company said its expected cash outlay at closing, after giving effect to RCA's equity rollover, its planned cash capitalization of RCA and transaction fees and expenses, would be approximately $4.3 billion. It also said it may pay up to $500 million in contingent consideration in fiscal year 2027 and fiscal year 2028 if predefined business objectives are achieved.
Cencora said it expects to fund the transaction with cash on hand and new debt financing, and that it has obtained $3.3 billion in bridge financing commitments. The transaction is subject to customary closing conditions, including receipt of required regulatory approvals.
The company said RCA has approximately 300 retina specialists across 23 states and 40 clinical trial sites. It also said it expects the acquisition to be approximately $0.35 accretive, net of estimated financing costs, to its adjusted diluted EPS in the first 12 months after closing, and that its fiscal year 2025 guidance does not include the impact of the acquisition.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Structure of the Retina Consultants of America Acquisition Price
Cencora said it will acquire Retina Consultants of America (RCA) for cash based on an enterprise value of approximately $4.6 billion, subject to a working capital and net-debt adjustment. It said it expects to hold approximately 85% ownership in RCA at closing.
Source · Based on the filing body and exhibits
Cash Outlay at Closing and Contingent Consideration
The company said its expected cash outlay at closing, after giving effect to RCA's equity rollover, its planned cash capitalization of RCA and transaction fees and expenses, would be approximately $4.3 billion. It also said it may pay up to $500 million in contingent consideration in fiscal year 2027 and fiscal year 2028 if predefined business objectives are achieved.
Source · Based on the filing body and exhibits
Financing and Closing Conditions
Cencora said it expects to fund the transaction with cash on hand and new debt financing, and that it has obtained $3.3 billion in bridge financing commitments. The transaction is subject to customary closing conditions, including receipt of required regulatory approvals.
Source · Based on the filing body and exhibits
RCA Scale and Cencora EPS Impact
The company said RCA has approximately 300 retina specialists across 23 states and 40 clinical trial sites. It also said it expects the acquisition to be approximately $0.35 accretive, net of estimated financing costs, to its adjusted diluted EPS in the first 12 months after closing, and that its fiscal year 2025 guidance does not include the impact of the acquisition.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…